Oncogene ( The downregulation of a tumor suppressor protein in hyperplastic lesions of the colon, as reported by Nittka et al. in this issue of Oncogene, sheds new light on the events that precede the genetic alterations known to contribute to the development of colon cancer. The downregulated protein is a cell adhesion molecule known as CEACAM1, recently implicated in generating apoptotic signals to ensure the development and maintenance of a single monolayer of epithelial cells around the lumena of the mammary gland. A role in inducing apoptosis is also reported by Nittka et al., and a reduction in apoptosis, due to loss of CEACAM1 expression proposed as an explanation for both the hyperplasia, and an increased likelihood of acquiring an oncogenic mutation, such as inactivation of the APC gene.
Colon cancers exhibit one of the clearest examples of the morphological progression of benign hyperplastic tissue to premalignant adenomas to overt neoplasia with genetic mutations progressively accumulating in the transition from adenomas to carcinomas. However, while it is well recognized that the earliest morphological changes in the colon include aberrant crypt foci (ACF) and hyperplastic polyps (HPP), their lack of genetic alterations such as mutations or deletions in the adenomatous polyposis coli (APC) gene have led to the conclusion that tumors do not arise from these cells. If not from these cells, then from where? One hypothesis is that the stem cells deep in the crypts accumulate early mutations in APC, lose their ability to differentiate, keep dividing, and gradually form tumors as they accumulate more mutations such as k-ras. Against this hypothesis is the finding that polyps free of APC mutations are frequently found together with adenomas that have APC mutations, and the fact that removal of these polyps decreases the incidence of colon cancer. In the paper by Nittka et al. in this issue of Oncogene, evidence that ACF and HPP cells are preneoplastic is presented. The authors have examined ACF and HPP lesions that represent the earliest stage of morphological abnormality for the expression of the tumor suppressor protein CEACAM1, and found that these lesions have the same reduced levels of expression as found in adenomas and adenocarcinomas. As expected, expression levels of APC were normal in these lesions, as was the expression pattern for b-catenin. Thus, silencing of CEACAM1 expression precedes changes in the gatekeeper gene APC, which, if they occur, predispose the cell to further oncogenic mutations. Nittka et al. propose that loss of CEACAM1 leads to reduced levels of apoptosis, thus leading to a net increase in proliferation in these cells. While the majority of the hyperproliferative cells regress, a small but significant portion go on to accumulate oncogenic mutations.
Now we turn our attention to the role of CEACAM1 in this process. Two important questions arise: first, what is the mechanism of CEACAM1 silencing and second what is the function of CEACAM1 in the colon? Let us start with the function of CEACAM1. CEA-CAM1 is a member of the CEA gene family that includes 28 genes on chromosome 19. Four members of the family that are expressed in normal colon are CEA, CEACAM1, CEACAM6, and CEACAM7. Only CEA-CAM1 has transmembrane and cytoplasmic domains (the other three are GPI-linked to the membrane), and only CEACAM1 is conserved in rodents, suggesting that the other three genes have novel functions in the gut. In fact, CEACAM1 is expressed on epithelial cells throughout the GI tract and in other lumen-forming organs such as the liver, breast, pancreas, prostate and kidney. However, even though CEACAM1 (as well as the other three genes expressed in the colon) have been termed cell-cell adhesion molecules, they exhibit an exclusively apical expression pattern in the colon (as well as other organs), calling into question this functional assignment. Using an in vitro model of mammary morphogenesis, where the expression pattern of CEA-CAM1 can be followed at each stage of development, we have shown that CEACAM1 is indeed found between cells early in organogenesis, and is essential in the initiation of an apoptotic program that eliminates the central cells that are not in contact with the basement membrane (Huang et al., 1999; Kirshner et al., 2003) . This not only creates a lumen, but also ensures that a monolayer of epithelial cells will be maintained along the basement membrane. Thus, CEACAM1 is a major player in the process termed anoikis that states that cells not in contact with basement membrane are doomed to die. Yet, the collaboration of CEACAM1 with integrinmediated attachment to the basement membrane indicates a more complicated mechanism, ensuring that more than one cellular function controls the apoptotic decision. Furthermore, there is evidence that the function of CEACAM1 changes during morphogenesis, because its expression pattern changes from between cells to apical during this process, and in the case of the breast, CEACAM1 is exocytosed into the lumen (Kirshner et al., 2004) . Since CEACAM1 is a homotypic cell adhesion molecule, its high levels on and in the lumen would potentially deliver apoptotic signals to hyperplastic cells that attempt to overgrow the single epithelium layer. Conversely, its absence on aberrant epithelium would open the door to hyperplastic growth. In support of this idea, Nittka et al. show that apoptotic figures are decreased in ACF and HP that lack CEACAM1 expression. Furthermore, they show in a model system that Jurkat cells that normally do not express CEACAM1 undergo apoptosis when transfected with the gene and treated with anti-CEACAM1 crosslinking antibodies. Similarly, the human colonic cancer cell line HT29, that expresses low levels of CEACAM1, undergoes apoptosis when treated with IFN-g (a cytokine that upregulates CEACAM1) and anti-CEA-CAM1 antibodies.
Nittka et al. have established that CEACAM1 downregulation precedes APC genetic changes, but, since no genetic changes have been observed in the CEACAM1 gene in either pre-cancerous or cancer tissue, the mechanism of gene silencing is left open. A recent report by Phan et al. (2004) has shown that CEACAM1 may be silenced by high expression levels of the transcription factor Sp2 in prostate cancer and recruitment of histone deacetylase (HDAC) to the promoter. Thus, it should be no surprise that CEA-CAM1 is downregulated in prostate cancer and that transfection of prostate cancer cells with CEACAM1 reduces their tumorigenicity in nude mice. However, while the study by Phan et al. documents that downregulation of CEACAM1 correlates with higher levels of Sp2 in high-grade prostate cancer, the scenario for hyperplastic prostate disease is normal expression of CEACAM1 (Busch et al., 2002) . Thus, the situation for colon vs prostate cancer progression is likely different. Nonetheless, a similar mechanism could be involved and the data suggesting a silencing mechanism via HDAC are exciting, since there is no evidence for promoter methylation (Phan et al., 2004) . It seems worth investigating the possibility that Sp2 represses CEA-CAM1 expression in ACF, HC, adenoma and colon cancer cells.
In view of the CEACAM1 findings, the colon cancer progression model of Fearon and Vogelstein (1990) must be modified. First, let us examine the normal colonic crypt. Stem cells at the base of the crypt proliferate into new colonic epithelial cells (Figure 1 , black box). CEACAM1 expression is low in these cells and gradually increases, reaching a peak at the lumenal surface (Figure 1, blue box) . b-Catenin expression is normal throughout the crypt and is predominantly located between cells where E-cadherin is expressed. Cells on the lumenal surface would be expected to have 'high' levels of apoptosis, mediated by CEACAM1, balancing the rate of proliferation from stem cells within the crypts. Proliferating cells that try to push over the epithelial monolayer would suffer an apoptotic fate based on their exposure to CEACAM1 and their lack of contact with the basement membrane.
Next, let us speculate on the events that occur in the hyperproliferative lesions (Figure 1, red box) . By an as yet unknown mechanism, one or more cells silence the CEACAM1 gene. The lack of CEACAM1 on these cells results in decreasing apoptotic numbers, disrupting homeostasis, slowly shifting the balance towards hyperproliferation. Cells in the hyperplastic polyp (or ACF) continue to divide slowly, but remain attached to the basement membrane. The proliferating polyp cells are exposed to a wide variety of mutagens in the lumen that may eventually lead to an APC mutation. Eventually, either both copies of APC are mutated or, through loss of the other copy of APC, the cells lose their critical gatekeeper gene, that otherwise maintains a check on rapid proliferation via the wnt/b-catenin pathway. Once this happens, the transition to adenoma occurs and, given further genetic changes, overt carcinomas are seen. This expansion of the colon cancer progression pathway answers some of the puzzles posed by the FearonVogelstein pathway, namely the lack of APC mutations in the stem cell compartment (Shih et al., 2001 ), but poses new ones. For example, what is the significance of finding HPPs together with polyps known as sessile serrated adenomas that have increased levels of hypermethylated genes (Batts, 2004) ? The 'expanded' pathway also suggests that epigenetic, rather than genetic, mechanisms are the key events predisposing to colon cancer. A lesson learned is the value of looking carefully at what is going on in pre-malignant lesions. There are also therapeutic implications. If we assume that the colonic lumen environment is inherently carcinogenic, and that proliferating cells are most susceptible to mutations, then it is essential to protect hyperplastic polyps, or remove them from this mutagenic environment.
An obvious next challenge is defining the mechanism of CEACAM1 silencing. Is it the recruitment of Sp2 and HDAC to the CEACAM1 promoter as suggested by Phan et al., and, if so, what triggers this epigenetic change? If the answers to these questions are found, are there yet earlier steps in the process? This is clearly a case of working backwards from overt cancer to rather benign lesions that merely predispose to cancer. When the mechanism is available, interventions that halt the process at the earliest step may be possible. Clues to the mechanism may present themselves in families that have high levels of colonic polyps not caused by inherited APC mutations.
